August 24, 2018
Polarean Imaging moving forward with Phase III trial of hyperpolarised 129-Xenon
“Medical imaging technology company Polarean Imaging announced on Thursday that the first patient has been enrolled in its Phase III FDA clinical trial, which aims to demonstrate non-inferiority of its drug-device combination using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.”
Confirmed by the AIM-traded firm, it is now in the midst of a Phase III clinical trial. A ‘head-to-head’ non-inferiority trial testing 129Xe MRI against 133-Xenon (133Xe) scintigraphy. The evaluation of two patient populations – candidates for lung lobe resection, and lung transplant procedures with a total of 80 patients in all.
Polarean, spun out of Dr. Dastiann Driehuys and Gary Cofer’s technology from the School of Medicine, launched their start-up in 2014.
[Originally posted by London South East — Aug 23, 2018]